- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Novartis-funded third‑party “medical education” videos were ruled promotional for unlicensed inclisiran, lacked clear sponsorship disclosure and certification, and breached multiple Code clauses…
Complaint alleged GSK promoted unlicensed products to the public via LinkedIn posts about Phase 3 RSV and Covid-19 antibody trials. Panel ruled…
Complaint about Lundbeck’s UK corporate website linking to global pages and alleged lack of reapproval. Panel found no promotion/public access breach, but…
Complaint about Leo executives’ online interviews on pharmaboardroom.com (UK-registered publisher). Panel/Appeal Board found the material was not promotional to UK audiences; no…
A senior AstraZeneca employee’s LinkedIn post linking to a vaccine efficacy press release, amplified by UK staff ‘likes’, was ruled promotion of…
BMJ ad framed as an acquisition announcement for Dificlir was ruled promotional. It lacked prescribing information and an adverse event reporting statement,…
Anonymous complaint alleged excessive rep calls, lack of SOP guidance and uncertified virtual materials (Jul 2020–Jun 2021). Panel found complainant didn’t meet…
Anonymous employee alleged improper planning/certification of advisory boards in Croatia, Poland and Hungary and conflicts of interest. Panel found allegations unproven; no…
A UK health professional challenged a GSK global LinkedIn post about positive interim Phase 2 results in a COVID-19 vaccine collaboration. Panel…
A medical oncologist alleged an AstraZeneca senior employee’s LinkedIn post promoted oncology portfolio/pipeline to the public. Panel found no direct product/pipeline promotion…
Forxiga website and rep messaging implied all patients can start 10mg with no uptitration. Key 5mg start for severe hepatic impairment was…
A hospital consultant complained about LinkedIn activity. PMCPA found breaches after an AstraZeneca employee liked/commented on a dapagliflozin post, potentially disseminating POM…
A Symbicort Turbohaler promotional email subject line omitted the non-proprietary name at first mention. PMCPA found breaches of Clauses 12.3 and 5.1,…
A Tillotts rep made an unplanned GP practice call about Asacol shortage/Octasa switch. The pharmacist said they don’t see reps, but the…
A Nilemdo press release said it “can be combined with other oral treatments” but didn’t make the simvastatin >40mg contraindication immediately apparent.…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.